

Rowan University

Rowan Digital Works

Rowan-Virtua School of Osteopathic Medicine
Faculty Scholarship

Rowan-Virtua School of Osteopathic Medicine

6-11-2023

Posttreatment Lyme Disease Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review and Comparison of Pathogenesis

Natalie Bai
Rowan University

Christie Richardson
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/som_facpub



Part of the [Bacterial Infections and Mycoses Commons](#), [Infectious Disease Commons](#), [Musculoskeletal Diseases Commons](#), [Nervous System Diseases Commons](#), [Pathological Conditions, Signs and Symptoms Commons](#), and the [Psychiatric and Mental Health Commons](#)

Recommended Citation

Bai, NA, Richardson, CS. Posttreatment Lyme disease syndrome and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review and comparison of pathogenesis. *Chronic Dis Transl Med.* 2023; 1-8. doi:10.1002/cdt3.74

This Article is brought to you for free and open access by the Rowan-Virtua School of Osteopathic Medicine at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua School of Osteopathic Medicine Faculty Scholarship by an authorized administrator of Rowan Digital Works.

REVIEW

Posttreatment Lyme disease syndrome and myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and comparison of pathogenesis

Natalie A. Bai | Christie S. Richardson

Department of Psychiatry, Rowan-Virtua School of Osteopathic Medicine, Mount Laurel, New Jersey, USA

Correspondence

Christie S. Richardson, Department of Psychiatry, Rowan-Virtua School of Osteopathic Medicine, 100 Century Pkwy, Ste 350, Mt Laurel, NJ 08054, USA.
Email: christiesleigher@gmail.com

Edited by Yi Cui

Abstract

Lyme disease is the most common vector-borne illness in the United States and has been causing significant morbidity since its discovery in 1977. It is well-documented that about 10% of patients properly treated with antibiotics never fully recover, but instead go on to develop a chronic illness dubbed, posttreatment Lyme disease syndrome (PTLDS) characterized by severe fatigue, cognitive slowing, chronic pain, and sleep difficulties. This review includes 18 studies that detail the symptoms of patients with PTLDS and uses qualitative analysis to compare them to myalgic encephalitis/chronic fatigue syndrome (ME/CFS), a strikingly similar syndrome. In the majority of the PTLDS studies, at least four of the six major symptoms of ME/CFS were also noted, including substantial impairment in activity level and fatigue for more than 6 months, post-exertional malaise, and unrefreshing sleep. In one of the included PTLDS articles, 26 of the 29 ME/CFS symptoms were noted. This study adds to the expanding literature on the post-active phase of infection syndromes, which suggests that chronic illnesses such as PTLDS and ME/CFS have similar pathogenesis despite different infectious origins.

KEYWORDS

chronic fatigue syndrome, Lyme disease, myalgic encephalitis, posttreatment Lyme disease syndrome, systematic review

Key points

- This systematic review uses qualitative analysis to compare posttreatment Lyme disease syndrome to myalgic encephalitis/chronic fatigue syndrome, both of which are post-active phases of infection syndromes.
- The result of this review suggests that chronic illnesses such as PTLDS and ME/CFS have similar pathogenesis despite different infectious origins.

1 | INTRODUCTION

Lyme disease is a rapidly spreading tick-borne illness caused by *Borrelia burgdorferi* endemic to much of the United States. There have been at least 30,000 reported cases annually since its discovery in 1977, and the CDC

published 275,589 reported cases from 2008 to 2015.¹ The earliest stage of Lyme disease is characterized by erythema migrans with or without constitutional symptoms, which resolves 90% of the time with antibiotics.² However, 10%–20% of patients go on to develop debilitating fatigue, myalgias, arthralgias, headaches,

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Chronic Diseases and Translational Medicine* published by John Wiley & Sons, Ltd on behalf of Chinese Medical Association.

sleep difficulties, cognitive slowing, and paresthesia.³ Oftentimes, these severe symptoms render patients unable to work or care for their loved ones.⁴ This collection of severe, continued Lyme disease symptoms, dubbed posttreatment Lyme disease syndrome (PTLDS) can persist for months to years. Although we have less knowledge about this syndrome, it is distinct from other Lyme disease sequelae, such as late-stage Lyme disease, Lyme neuroborreliosis, and antibiotic-refractory Lyme arthritis. The underlying pathophysiology of PTLDS is unknown and the validity of the diagnosis is often questioned in the medical community.^{2,3} This review seeks to compile and comprehensively review evidence that validates that PTLDS is not only a true chronic disease, but that its symptoms and timeline are strikingly similar to other chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long coronavirus disease (COVID).

PTLDS follows a similar pattern to a more recently prevalent disease, long COVID, a condition in which patients appear to have cleared COVID-19 according to objective lab results yet continue to suffer from subjective symptoms including disabling fatigue, post-exertional exhaustion, shortness of breath, and generalized malaise.⁵ Long COVID itself has been linked to ME/CFS as many long COVID patients are satisfying the Institute of Medicine criteria for ME/CFS.⁵ ME/CFS is characterized by fatigue, cognitive slowing, headaches, flu-like symptoms, arthralgias, and myalgias.⁵ ME/CFS is a diagnosis of exclusion and requires the presence of severe fatigue interfering with daily life for greater than 6 months and moderate, severe, or substantial intensity of symptoms at least half of the time. Patients must have the following: (1) new onset inability/reduction in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities that last greater than 6 months and are not relieved with rest or caused by excessive activity; (2) worsening of these symptoms after prolonged physical or mental exertion; (3) unrefreshing sleep; and (4) cognitive impairment and/or orthostatic intolerance.^{5,6} The standard of care for ME/CFS is supportive treatment, often with the same medications used to treat fibromyalgia, although in most cases there is little improvement in symptoms.⁶ Accepted treatment for long COVID is similar; it includes evaluation of chronic symptoms with supportive care on a case-by-case basis.⁵

Like long COVID and ME/CFS, the exact pathophysiology of PTLDS is still unknown. Several studies have documented elevations of pro-inflammatory markers and disturbances in energy production/metabolic functions. A case-control study by Fitzgerald et al.⁷ identified metabolic differences between healthy controls and those with PTLDS. These findings are similar to results that have been seen with ME/CFS, which have a major effect on energy production and provide a possible mechanism for patients' chronic fatigue.⁸ Other hypotheses point to antibiotic-refractory Lyme arthritis as an example of *Borrelia burgdorferi* causing a localized

pro-inflammatory state in joints after the infection has cleared.⁹ One study by Steere et al.¹⁰ found that patients with HLA-DR alleles, which are linked to autoimmune diseases, are more likely to develop Lyme arthritis. Another study from Uhde et al.¹¹ found that patients with PTLDS and antibiotic-refractory Lyme arthritis both have elevated C-reactive protein levels. Other potential markers including IL-23, CCL19, and anti-neural antibodies have been found to be elevated in patients with PTLDS.¹²⁻¹⁴ This further strengthens arguments that these chronic symptoms could be due to immune dysregulation.

Although there are over one million patients suffering from PTLDS in the United States, there is still a paucity of potential treatments.¹⁵ ME/CFS has a larger body of research, and if found to have similar pathophysiology to PTLDS, that research could potentially improve the lives of these patients. This systematic review seeks to compare documented symptoms of ME/CFS to PTLDS to reveal similarities between the two conditions and propose that Lyme disease is yet another way to develop a post-active phase of infection syndrome. To uphold this argument, this study uses a qualitative approach to the systematic review to present the symptoms of PTLDS and compare them to the most common symptoms of ME/CFS.

2 | METHODS

PubMed and MEDLINE/Ovid were the primary databases used to search for articles that documented the symptoms of PTLDS. Articles were included up until November 15, 2022. There is no standardized name for PTLDS, so alternative search phrases of "chronic Lyme disease" and "posttreatment Lyme disease" were both used. This process followed the PRIMSA guideline for systematic review.¹⁶

On PubMed, "chronic Lyme disease" yielded 1415 results, and "posttreatment Lyme disease" yielded 327 results. On Medline, "posttreatment Lyme disease" yielded 50 results, and "chronic Lyme disease" yielded 231 results. Titles and abstracts of the resulting articles were reviewed, and articles that documented the individual symptoms of patients diagnosed with PTLDS were selected. To fit these criteria, patients in the article had to be diagnosed with Lyme disease and treated with antibiotics according to the standard of treatment with no relief from their symptoms. Ideally, articles included only documented patients who suffered from PTLDS symptoms for at least 6 months to correlate well with ME/CFS diagnostic inclusion criteria. However, this search returned too few articles. Therefore, articles were included that documented PTLDS symptoms in patients for at least 3 months posttreatment with antibiotics. All articles regarded PTLDS as a diagnosis of exclusion and symptoms could not be related to another ailment.

Articles were excluded if they did not describe the symptoms of the study participants or other related conditions such as Lyme arthritis or late-stage Lyme disease without antibiotic treatment. The chart displayed is adopted from a study by Lim and Son¹⁷ and used previously in a study by Wong and Weitzer⁵ to compare ME/CFS to long COVID.^{5,17}

3 | RESULTS

The initial search criteria resulted in 2023 articles. Using the above search criteria and removing duplicate and unrelated articles, 52 articles remained. The full texts of the remaining articles were examined, and articles that did not report the PTLDS symptoms of the participants were excluded. For example, exclusion criteria impeded the authors from including a study by Vargas et al.¹⁸ published in 2021 due to its inclusion of one participant who had confirmed antibiotic-refractory Lyme arthritis. A study by Uhde et al.¹⁹ that examined the level of C-reactive protein elevation in patients with ME/CFS in comparison to those with PTLDS was excluded because it did not list the clinical symptoms of its participants. After an exhaustive search for articles that fit the criteria, the systematic review included 18 articles.

The 18 PTLDS articles are described in Table 1, which includes the total number of patients, the location of study, the time elapsed since initial antibiotic treatment, how results were gathered, the percentage of patients with confirmed PTLDS who reported each specific symptom, and the risk of bias. The articles are organized from the largest to smallest sample size. Sample sizes smaller than 50 participants were documented in 50% of the included articles. Small sample sizes in each individual study are recognized to be the largest threat to the integrity of the data as a whole.

In Table 2, reported ME/CFS symptoms are compared with reported PTLDS symptoms. The symptoms that are well-established and a requirement for diagnosis are documented as the primary symptoms, and the remaining symptoms attributed to ME/CFS are listed below the primary.^{5,6,17} Out of the 18 included studies, 15 documented the symptoms as lasting greater than 6 months. The other three studies recognized that most of their patients had been suffering for over 6 months but chose not to require 6 months of symptoms for study inclusion. Each of the symptoms attributed to ME/CFS were reported by at least one study in the setting of PTLDS except three: lymphadenopathy, susceptibility to viruses, and food sensitivities. These were the same symptoms that were not reported by any patients with long COVID as documented in the systematic review by Wong and Weitzer.⁵ Symptoms that appeared to be unique to PTLDS included paresthesia, tremor, and stiff neck, with paresthesia being the most common.

The most common overlapping symptoms included fatigue and brain fog. Both symptoms were reported by participants in 15 studies, followed by arthralgia, myalgia, and memory difficulties which were seen in 11 studies. It should be noted, however, that three of the studies were focused only on cognitive issues. Although they did not assess any other symptoms in their patients who met PTLDS criteria, it is quite possible that the patients were also suffering from fatigue and other symptoms. In the study by Nilsson et al.,²⁰ all of the participants satisfied the diagnostic criteria of ME/CFS if not for their documented PTLDS.

4 | DISCUSSION

The purpose of this systematic review is to fill a recognized gap in data on PTLDS by comparing it to ME/CFS. Both syndromes were defined in the last 30 years and have different inciting factors. However, as the evidence in this review suggests, the resulting chronic syndromes are largely the same.

As seen in Table 2, the symptoms of ME/CFS outlined by Wong and Weitzer in 2021 are comparable to the PTLDS symptoms described by participants in the 18 included articles. Of the 29 ME/CFS symptoms, all but three (lymphadenopathy, susceptibility to viruses, and food sensitivities) were reported in at least one included article as experienced by their participants. Of the six major diagnostic symptoms, over half of the articles reported at least four. The most shared characteristics are symptoms lasting greater than 6 months, fatigue, sleep difficulties, and brain fog. Although post-exertional malaise, part of the major criteria for ME/CFS, was not cited as often, it is possible that this criterion was included with fatigue/malaise for most of the articles. Other similar symptoms included arthralgias, myalgias, memory difficulties, and headaches. The overlap of symptoms makes a compelling argument that PTLDS and ME/CFS are very similar.

These symptoms are highly characteristic of global inflammatory processes. Additional research links the two syndromes even more tightly as inflammatory conditions with an infectious nidus. A study of children with ME/CFS found elevations of IL-23 which is an inflammatory marker also found to be elevated in patients with documented PTLDS.^{14,37,38} Elevation in pro-inflammatory cytokines in ME/CFS is well-documented and increasing evidence compiled on PTLDS has also identified elevated inflammatory markers including C-reactive protein, IL-23, CCL19, and anti-neural antibodies.¹¹⁻¹⁴ A study by Fitzgerald et al.⁷ also documented metabolic differences between healthy controls and patients diagnosed with PTLDS. This finding was very similar to results in patients with ME/

TABLE 1 Studies included in the review.

Authors	No. of patients	Location	Time at assessment	Methodology	Key findings	Other findings
Hill et al. ⁴	82	USA	>6 months	Questionnaires	Physical functioning issues, social functioning issues, low energy	Increased pain, psychiatric issues
Nilsson et al. ²⁰	85	Sweden	>6 months	Interview	Fatigue (66%), neurocognitive symptoms (59%), dizziness (38%), sleep disturbance (36%), reduced endurance (33%)	Neurological issues (84%), musculoskeletal issues (78%), malaise (76%), arthralgias (53%)
Horowitz et al. ²¹	165	USA	>6 months	Survey/interview	Fatigue (88%), memory issues/brain fog (77.6%), sleep issues (63.7%), speech/writing difficulties (53.4%)	Myalgia/arthralgias (74%), headache (44.8%), paresthesias (49.1%), sweats/flushing (48.5%)
Berende et al. ²²	280	USA	>4 months	Questionnaires	Fatigue (95%), neurocognitive issues (86%)	Arthralgia (90%), myalgia (80%), sensory issues (76%), neuralgia (15%)
Klempner et al. ²³	129	USA	>6 months	Questionnaires	Fatigue/malaise (90%), neurocognitive symptoms (72%), sleep disturbance (51%)	Arthralgia/myalgia (92%), dyesthesia (70%), headache (42%)
Baarsma et al. ²⁴	15	Netherlands	>6 months	Focus group/interview	Fatigue (87%), cognitive problems (53.3%)	Myalgia/arthralgia (47%), impaired coordination (33%), visual/auditory impairments (33%), feeling feverish/chills (33%)
Aucott et al. ²⁵	234	USA	6 months-1 year	Questionnaires	Fatigue, difficulty focusing/difficulty finding words/memory difficulty, difficulty sleeping	Muscle pain, joint pain/swelling, paresthesias, depression/anxiety/irritability, headache, chills/sweats, fevers, photophobia/visual clarity, tinnitus, dizziness, sore throat, diarrhea
Rebman et al. ²⁶	212	USA	Median 1.67 years	Questionnaires	Fatigue, memory issues, difficulty focusing, word-finding difficulties, difficulty sleeping	Myalgias, arthralgias/joint swelling, headache, paresthesias, photophobia, vision issues, fever/chills/sweats, nausea, depression, anxiety, irritability
Touradji et al. ²⁷	124	USA	>6 months	Questionnaires	Cognitive complaint (91.7%)	Depression (22%), anxiety (9%)
Krupp et al. ²⁸	55	USA	>6 months	Interview and Questionnaires	Severe fatigue, cognitive slowing	
Aprielle et al. ²⁹	42	USA	>2 years	Questionnaires	Fatigue (64%), sleep disturbance (45%), poor memory (38%), poor concentration/word finding (33%)	Myalgia (67%), arthralgia (55%)
Murray et al. ³⁰	29	USA	>6 months	Questionnaires	Fatigue, low physical functioning, cognitive difficulties	Chronic pain, depression
Musonera et al. ³¹	27	Canada	Not documented	Patient chart review	Fatigue (70%), insomnia (19%), difficulty concentrating (15%)	Headache (70%), arthralgia (59%), myalgias (48%), paresthesias (26%), tremor (15%)

TABLE 1 (Continued)

Authors	No. of patients	Location	Time at assessment	Methodology	Key findings	Other findings
Turk et al. ³²	15	USA	>12 months	Questionnaires	Fatigue (87%), concentration/memory issues (73%), word-finding difficulties (40%), sleep disturbances (33%), dizziness/lightheadedness (7%)	Arthralgias (33%), mood disturbance (33%), headache (27%), paresthesia (27%), myalgias (20%), stiff neck (20%), tinnitus (7%)
Weitzner et al. ³³	14	USA	>6 months	Questionnaires/interviews	Fatigue (79%), memory/concentration impairment (27%), dizziness (35%)	Headache (50%), arthralgia (50%), feverish (43%), stiff neck (43%), anorexia (36%), myalgias (35%), paresthesia (27%), prolonged PR on EKG (15.4%), cough (14.3%)
Coyle et al. ³⁴	12	USA	>6 months	Interview	All 12 patients met CFS criteria, 6 met minor criteria	
Marvel et al. ³⁵	12	USA	>9 months	Questionnaires	Cognitive decline	Slower working memory
Novak et al. ³⁶	10	USA	>6 months	Neurological evaluation/Questionnaires	Orthostatic drop (70%), lightheadedness (80%)	Autonomic dysfunction (80%), aching pain (100%), paresthesia (80%), GI upset (40%)

CFS from a previous study, with both articles showing changes in glycerophospholipid, aromatic and branched-chain amino acid, carnitine, bile acid, fatty acid, and sphingolipid metabolism.⁸ As there is no standardized test for ME/CFS or PTLDS, developing diagnostic biomarkers is the key to streamlining diagnosis.^{12,13}

In addition to documenting the symptoms of their participants, studies have also hypothesized the pathophysiology of PTLDS. Although there is currently no evidence that *Borrelia burgdorferi* remains in human tissue after adequate treatment, several studies have shown improvement in fatigue after long-term intravenous antibiotics.³ A retrospective chart review by Horowitz and Freeman²¹ which followed 200 patients showed that Dapsone combination treatment for 6 months was statistically significant in reducing the severity of eight major PTLDS symptoms. However, two studies published in the *New England Journal of Medicine* in 2001 and 2016 showed no statistically significant differences in those treated by antibiotics in comparison to placebo.^{22,23} In consequence, it is not the standard of care to treat PTLDS with additional antibiotics.^{2,39} Depending on the chronicity of their Lyme disease upon diagnosis, patients are treated with one finite antibiotic regiment.² Early-stage patients receive 10 days of Doxycycline and late-stage cases with neurologic manifestation receive intravenous Ceftriaxone for 28 days; any further antibiotic regimens are not recommended.² Patients can choose to participate in research studies that explore if long-term antibiotic treatment would improve their chronic PTLDS symptoms.²¹ It is important to note that PTLDS still carries a degree of stigma in the medical community. Many practitioners argue against its existence and others struggle to diagnose it without a standardized test.^{24,40} Due to these factors, patients who satisfy the criteria for PTLDS may have had negative experiences in the healthcare field and experienced discrepancies between symptom onset and diagnosis. This may affect data in patients who may exaggerate symptoms to obtain care or conversely may be the reason for the smaller sample sizes in the included articles. This may also contribute to many patients with the disease remaining undiagnosed.

Limitations for most of the articles in this review include a small sample size and homogeneous participant population, with a great majority of the patients being of a higher socioeconomic status and White race. Many of the studies also relied on patients volunteering themselves or being referred by other clinicians which may have skewed the results. For future literature, it would be encouraging to see more studies comparing ME/CFS and PTLDS responses to different treatments to find even more similarities.

TABLE 2 Comparison of compiled ME/CFS symptoms to reported PTLDS symptoms.

Items	ME/CFS criteria symptoms	Reference number of PTLDS studies with matching symptoms	Non-ME/CFS criteria symptoms
Major ME/CFS criteria	Duration ≥ 6 months	4, 20, 23, 25, 27, 29, 30–34, 36–38, 40	
	Fatigue/reduced daily activity	4, 20, 23–25, 27, 29, 30, 32–38	
	Post-exertional malaise	4, 20, 32, 38	
Neurologic/pain	Sleep difficulties	20, 23, 25, 29, 30, 33, 35, 36, 38	
	Myalgia	20, 23–25, 27, 29, 30, 33, 35–37	
	Muscle weakness	20	
	Motor disturbance	20, 27	
	Generalized hyperalgesia(increased pain)	4, 20, 24, 25, 27, 34, 40	
	Joint pain/arthritis	20, 23–25, 27, 29, 30, 33, 35–37	
	Headaches	20, 23, 25, 29, 30, 35, 36	
	Hypersensitivity to noise/light	29, 30	
	Tinnitus, double vision	20, 24, 27, 29, 30, 36	
		20, 23, 24, 29, 35, 36, 37, 40	Paresthesias
	36, 37	Stiff neck	
	35	Tremor	
Neurocognitive/psychiatric	Cognitive slowing/brain fog	20, 23, 24, 25, 27, 29, 30–37, 39	
	Memory difficulties/forgetfulness	20, 23, 24, 27, 29–31, 33, 34, 36, 37	
	Attention difficulties	29, 30, 33, 35–37	
	Psychiatric issues (depression, anxiety, etc.)	4, 20, 29, 30, 31, 34, 36	
Neuroendocrine	Thermostatic instability	20, 23, 27, 29, 30, 37, 40	
	Anorexia	37	
Autonomic	Orthostatic intolerance/dizziness	20, 24, 29, 36, 37, 40	
	Cardiovascular (palpitations, chest pain, etc.)	20	
	Respiratory (dyspnea, etc.)	20	
	Gastrointestinal (nausea, vomiting, diarrhea)	20, 29, 30, 40	
	Incontinence	20, 40	
Immune system	Fever/chills	27, 29, 30	
	Flu-like symptoms	29	
	Sore throat	29	
	Lymphadenopathy		
	Susceptibility to viruses		
	Food sensitivities		

Abbreviations: ME/CFS, myalgic encephalitis/chronic fatigue syndrome; PTLDS, posttreatment Lyme disease syndrome.

5 | CONCLUSIONS

This systematic review seeks to highlight the similarities between ME/CFS and PTLDS. From a vast literature review, 18 articles that document the symptoms of

patients with PTLDS were chosen. The 18 PTLDS studies cited all but three of the 29 ME/CFS symptoms and most of the articles documented four of the six major ME/CFS symptoms. Both syndromes begin after an infectious event from which approximately 10% of patients never

truly recover. Pro-inflammatory states and changes in metabolism are the foremost hypotheses to explain the pathophysiology of each illness. This review uses qualitative data to make an argument that ME/CFS and PTLDS are similar in nature. It remains to be seen whether either illness will have a diagnostic test or effective treatment to improve the lives of the patients who are currently suffering.

AUTHOR CONTRIBUTIONS

Natalie A. Bai reviewed the literature. Natalie A. Bai and Christie S. Richardson contributed equally to writing and revision of the manuscript.

ACKNOWLEDGMENTS

We would like to thank Dr. Kenneth J. Friedman, Ph.D., for his guidance in writing this paper.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in this article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Not applicable.

REFERENCES

- Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme disease—United States, 2008–2015. *MMWR Surveill Summ.* 2017;66(22):1–12. doi:10.15585/mmwr.ss6622a1
- Hu L, Shapiro ED. *Treatment of Lyme Disease.* UpToDate. Accessed May 24, 2021. <https://www.uptodate.com/contents/treatment-of-lyme-disease?search=lyme+disease+treatment>
- Wong KH, Shapiro ED, Soffer GK. A review of post-treatment Lyme disease syndrome and chronic Lyme disease for the practicing immunologist. *Clin Rev Allergy Immunol.* 2022;62(1):264–271. doi:10.1007/s12016-021-08906-w
- Hill EM, Frost A. Illness perceptions, coping, and health-related quality of life among individuals experiencing chronic Lyme disease. *Chronic Illn.* 2022;18:426–438. doi:10.1177/1742395320983875
- Wong TL, Weitzer DJ. Long COVID and myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a systemic review and comparison of clinical presentation and symptomatology. *Medicina.* 2021;57:418. doi:10.3390/medicina57050418
- Gluckman S. *Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.* UpToDate. Accessed November 15, 2022. https://www.uptodate.com/contents/treatment-of-myalgic-encephalomyelitis-chronic-fatigue-syndrome?search=chronic%20fatigue%20syndrome&topicRef=2740&source=see_link
- Fitzgerald BL, Graham B, Delorey MJ, et al. Metabolic response in patients with post-treatment Lyme disease symptoms/syndrome. *Clin Infect Dis.* 2021;73(7):e2342–e2349. doi:10.1093/cid/ciaa1455
- Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. *Mol BioSyst.* 2017;13:371–379. doi:10.1039/c6mb00600k
- Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. *Nat Rev Dis Primers.* 2016;2:16090. doi:10.1038/nrdp.2016.90
- Steere AC, Klitz W, Drouin EE, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a *Borrelia burgdorferi* peptide. *J Exp Med.* 2006;203:961–971. doi:10.1084/jem.20052471
- Uhde M, Ajamian M, Li X, Wormser GP, Marques A, Alaadini A. Expression of C-Reactive protein and serum amyloid A in early to late manifestations of Lyme disease. *Clin Infect Dis.* 2016;63(11):1399–1404. doi:10.1093/cid/ciw599
- Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. *Clin Vaccine Immunol.* 2016;23(9):757–766. doi:10.1128/CVI.00071-16
- Chandra A, Wormser GP, Klemperer MS, et al. 2010 anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. *Brain Behav Immun.* 2010;24:1018–1024. doi:10.1016/j.bbi.2010.03.002
- Strle K, Stupica D, Drouin EE, Steere AC, Strle F. Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. *Clin Infect Dis.* 2014;58(3):372–380. doi:10.1093/cid/cit735
- Maksimyan S, Syed MS, Soti V. Post-treatment Lyme disease syndrome: need for diagnosis and treatment. *Cureus.* 2021;13(10):e18703. doi:10.7759/cureus.18703
- Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ.* 2021;372:n160. doi:10.1136/bmj.n160
- Lim EJ, Son CG. Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *J Transl Med.* 2020;18:289. doi:10.1186/s12967-020-02455-0
- Vargas SE, Guillen M, Stout CD, et al. Characterizing post-treatment Lyme disease syndrome: a mixed methods study of patients at a Lyme Disease Clinic in Rhode Island. *R I Med.* 2021;104(8):30–34.
- Uhde M, Indart A, Fallon BA, et al. C-reactive protein response in patients with post-treatment Lyme disease symptoms versus those with myalgic Encephalomyelitis/chronic fatigue syndrome. *Clin Infect Dis.* 2018;67(8):1309–1310. doi:10.1093/cid/ciy299
- Nilsson K, Skoog E, Jones V, et al. A comprehensive clinical and laboratory evaluation of 224 patients with persistent symptoms attributed to presumed tick-bite exposure. *PLoS One.* 2021;16:e0247384. doi:10.1371/journal.pone.0247384
- Horowitz RI, Freeman PR. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: Part 1. *Int J Gen Med.* 2019;12:101–119. doi:10.2147/IJGM.S193608
- Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. *N Engl J Med.* 2016;374(13):1209–1220. doi:10.1056/NEJMoa1505425
- Klemperer MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med.* 2001;345:85–92. doi:10.1056/NEJM200107123450202
- Baarsma ME, Claassen SA, van der Horst HE, Hovius JW, Sanders JM. Knowing the entire story—a focus group study on patient experiences with chronic Lyme-associated symptoms (chronic Lyme disease). *BMC Prim Care.* 2022;23:139. doi:10.1186/s12875-022-01736-5
- Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. *Int J Infect Dis.* 2022;116:230–237. doi:10.1016/j.ijid.2022.01.033
- Rebman AW, Yang T, Aucott JN. Symptom heterogeneity and patient subgroup classification among us patients with post-

- treatment Lyme disease: an observational study. *BMJ Open*. 2021;11:e040399. doi:10.1136/bmjopen-2020-040399
27. Touradji P, Aucott JN, Yang T, Rebman AW, Bechtold KT. Cognitive decline in post-treatment Lyme disease syndrome. *Arch Clin Neuropsychol*. 2019;34:455-465. doi:10.1093/arclin/acy051
 28. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology*. 2003;60(12):1923-1930. doi:10.1212/01.wnl.0000071227.23769.9e
 29. Wills AB, Spaulding AB, Adjemian J, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. *Clin Infect Dis*. 2016;62(12):1546-1551. doi:10.1093/cid/ciw189
 30. Murray L, Alexander C, Bennett C, Kuvaldina M, Khalsa G, Fallon B. Kundalini yoga for post-treatment Lyme disease: a preliminary randomized study. *Healthcare*. 2022;10(7):1314. doi:10.3390/healthcare10071314
 31. Musonera JB, Valiquette L, Baron G, et al. Management and clinical outcomes of Lyme disease in acute care facilities in 2 endemic regions of Quebec, Canada: a multicentre retrospective cohort study. *CMAJ Open*. 2022;10(2):E570-E576. doi:10.9778/cmajo.20210063
 32. Turk SP, Lumbard K, Liepshutz K, et al. Post-treatment Lyme disease symptoms score: developing a new tool for research. *PLoS One*. 2019;14:e0225012. doi:10.1371/journal.pone.0225012
 33. Weitzner E, McKenna D, Nowakowski J, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. *Clin Infect Dis*. 2015;61(12):1800-1806. doi:10.1093/cid/civ735
 34. Coyle PK, Krupp LB, Doscher C, Amin K. *Borrelia burgdorferi* reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. *Clin Infect Dis*. 1994;18(suppl 1):S24-S27. doi:10.1093/clinids/18.supplement_1.s24
 35. Marvel CL, Alm KH, Bhattacharya D, et al. A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease. *PLoS One*. 2022;17(10):e0271425. doi:10.1371/journal.pone.0271425
 36. Novak P, Felsenstein D, Mao C, Octavien NR, Zubcevic N. Association of small fiber neuropathy and post treatment Lyme disease syndrome. *PLoS One*. 2019;14:e0212222. doi:10.1371/journal.pone.0212222
 37. Kuwabara T, Ishikawa F, Yasuda T, et al. CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. *J Immunol*. 2009;183:2513-2521. doi:10.4049/jimmunol.0800729
 38. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Board on the Health of Select Populations Institute of Medicine. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness*. National Academies Press; 2015. doi:10.17226/19012
 39. Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post-Lyme disease syndrome in a commercially insured sample. *Clin Infect Dis*. 2018;67(10):1568-1574. doi:10.1093/cid/ciy329
 40. Gentilini M, Bricaire F. Chronic Lyme disease: a scam that should be condemned. *Med Mal Infect*. 2019;49(2):83-84. doi:10.1016/j.medmal.2019.01.001

How to cite this article: Bai NA, Richardson CS. Posttreatment Lyme disease syndrome and myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and comparison of pathogenesis. *Chronic Dis Transl Med*. 2023;1-8. doi:10.1002/cdt3.74